DNAPrint Interest Expense from 2010 to 2026
DNAPrint Genomics' Interest Expense is steady over the last several years with stable swings. Interest Expense is predicted to flatten to 0.00. Interest Expense is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. View All Fundamentals
Check out the analysis of DNAPrint Genomics Correlation against competitors. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.
Interest Expense | First Reported 2001-12-31 | Previous Quarter 363.9 K | Current Value 222 K | Quarterly Volatility 615.8 K |
Check DNAPrint Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DNAPrint Genomics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.8 M or Total Revenue of 2.9 M, as well as many indicators such as Price To Sales Ratio of 1.49, Dividend Yield of 0.0 or Days Sales Outstanding of 12.22. DNAPrint financial statements analysis is a perfect complement when working with DNAPrint Genomics Valuation or Volatility modules.
DNAPrint | Interest Expense | Build AI portfolio with DNAPrint Stock |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of DNAPrint Genomics Correlation against competitors. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Can Biotechnology industry sustain growth momentum? Does DNAPrint have expansion opportunities? Factors like these will boost the valuation of DNAPrint Genomics. Projected growth potential of DNAPrint fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating DNAPrint Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DNAPrint Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DNAPrint Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DNAPrint Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.